Department of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, No. 12 of Jiankang Road, Chang-an District, Shijiazhuang, 050011, Hebei, China.
Clin Transl Oncol. 2024 Oct;26(10):2701-2717. doi: 10.1007/s12094-024-03477-6. Epub 2024 Apr 20.
Transmembrane protein 92 (TMEM92) has been implicated in the facilitation of tumor progression. Nevertheless, comprehensive analyses concerning the prognostic significance of TMEM92, as well as its role in immunological responses across diverse cancer types, remain to be elucidated.
In this study, data was sourced from a range of publicly accessible online platforms and databases, including TCGA, GTEx, UCSC Xena, CCLE, cBioPortal, HPA, TIMER2.0, GEPIA, CancerSEA, GDSC, exoRBase, and ImmuCellAI. We systematically analyzed the expression patterns of TMEM92 at both mRNA and protein levels across diverse human organs, tissues, extracellular vesicles (EVs), and cell lines associated with multiple cancer types. Subsequently, analyses were conducted to determine the relationship between TMEM92 and various parameters such as prognosis, DNA methylation, copy number variation (CNV), the tumor microenvironment (TME), immune cell infiltration, genes with immunological relevance, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), and half-maximal inhibitory concentration (IC50) values.
In the present study, we observed a pronounced overexpression of TMEM92 across a majority of cancer types, which was concomitantly associated with a less favorable prognosis. A notable association emerged between TMEM92 expression and both DNA methylation and CNV. Furthermore, a pronounced relationship was discerned between TMEM92 expression, the TME, and the degree of immune cell infiltration. Intriguingly, while TMEM92 expression displayed a positive correlation with macrophage presence, it inversely correlated with the infiltration level of CD8 + T cells. Concurrently, significant associations were identified between TMEM92 and the major histocompatibility complex, TMB, MSI, and MMR. Results derived from Gene Set Enrichment Analysis and Gene Set Variation Analysis further substantiated the nexus of TMEM92 with both immune and metabolic pathways within the oncogenic context.
These findings expanded the understanding of the roles of TMEM92 in tumorigenesis and progression and suggest that TMEM92 may have an immunoregulatory role in several malignancies.
跨膜蛋白 92(TMEM92)已被牵涉到促进肿瘤进展中。然而,关于 TMEM92 的预后意义及其在不同癌症类型中的免疫反应中的作用的全面分析仍有待阐明。
在这项研究中,数据来源于一系列可公开访问的在线平台和数据库,包括 TCGA、GTEx、UCSC Xena、CCLE、cBioPortal、HPA、TIMER2.0、GEPIA、CancerSEA、GDSC、exoRBase 和 ImmuCellAI。我们系统地分析了 TMEM92 在多种人类器官、组织、细胞外囊泡(EVs)和与多种癌症类型相关的细胞系中的 mRNA 和蛋白质水平的表达模式。随后,进行了分析以确定 TMEM92 与各种参数之间的关系,例如预后、DNA 甲基化、拷贝数变异(CNV)、肿瘤微环境(TME)、免疫细胞浸润、具有免疫学相关性的基因、肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)、错配修复(MMR)和半最大抑制浓度(IC50)值。
在本研究中,我们观察到 TMEM92 在大多数癌症类型中显著过表达,同时与预后较差相关。TMEM92 表达与 DNA 甲基化和 CNV 之间存在显著关联。此外,在 TMEM92 表达、TME 和免疫细胞浸润程度之间也发现了显著的关系。有趣的是,虽然 TMEM92 表达与巨噬细胞的存在呈正相关,但与 CD8+T 细胞的浸润水平呈负相关。同时,TMEM92 与主要组织相容性复合体、TMB、MSI 和 MMR 之间也存在显著关联。基因集富集分析和基因集变异分析的结果进一步证实了 TMEM92 与致癌环境中的免疫和代谢途径之间的联系。
这些发现扩展了对 TMEM92 在肿瘤发生和进展中的作用的理解,并表明 TMEM92 可能在几种恶性肿瘤中具有免疫调节作用。